# Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

> **NCT01373151** · PHASE2 · COMPLETED · sponsor: **CSL Behring** · enrollment: 418 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** BMS-945429 Placebo
- **BIOLOGICAL:** BMS-945429
- **BIOLOGICAL:** BMS-945429
- **BIOLOGICAL:** BMS-945429
- **BIOLOGICAL:** BMS-945429
- **DRUG:** Methotrexate
- **DRUG:** Methotrexate
- **DRUG:** Methotrexate Placebo
- **DRUG:** Methotrexate
- **DRUG:** Adalimumab Placebo
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT01373151
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-09
- **Final completion:** 2015-06
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2021-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01373151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01373151, "Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01373151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*